Action Point Financial Planning’s Acadia Pharmaceuticals ACAD Stock Holding History

Action Point Financial Planning’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5K	Buy	+100	New	+$2.2K	﹤0.01%	2153

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Action Point Financial Planning's ACAD Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 100 shares worth $2.5K. The stake represents ﹤0.01% of the portfolio and ranks #2153 among its holdings.

350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Action Point Financial Planning held 100 shares of Acadia Pharmaceuticals worth $2.5K as of Q2 2026.
Acadia Pharmaceuticals was a new Action Point Financial Planning position in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #2153 holding.
350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.